Serenity and Relief for Patients with Anxiety

The first prescription digital therapeutic designed to treat Generalized Anxiety Disorder (GAD) and Panic Disorder (PD)

reVIVE™ for Generalized Anxiety Disorder and Panic Disorder

Pear Therapeutics has developed reVIVE™, a prescription digital therapeutic to be used in combination with medication for treating GAD and PD

Patient-Facing Smartphone Application  + Benzodiazepine Medication

What is reVIVE™?

  • reVIVE™ offers an innovative method for treating GAD, a psychiatric disease characterized by long-lasting anxiety not focused on a specific object or situation, as well as PD, a disease in which debilitating anxiety and fear can arise without reasonable cause1
  • reVIVE™ utilizes a combination of assessments, dosing and therapeutic paradigms to treat anxiety conditions
  • By tailoring the prescription digital therapeutic to the pharmacokinetics of the benzodiazepine, reVIVE™ may be able to enhance clinical outcomes

reVIVE™ as a Prescription Digital Therapeutic for Treating GAD and PD

reVIVETM produces a significant decrease in self-assessed measures of anxiety in patients diagnosed with GAD

  • A randomized controlled trial, involving 25 GAD patients, was carried out over 8 sessions and included both relaxation and exposure techniques.
  • The following psychometric questionnaires were administered to each patient before and after treatment:
    • Beck Anxiety Inventory (BAI) – a 21-item scale measuring cognitive, behavioral and physiological symptoms of anxiety
    • Hamilton Anxiety Rating Scale (HAM-A) – a 14-item scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety)
    • State-Trait Anxiety Inventory Form (STAI) – a 2-scale questionnaire including 20 items each that differentiates between the temporary condition of “state anxiety” (STAY-Y1) and the more general and long-standing quality of “trait anxiety” (STAY-Y2)
  • Mean scores from psychometric questionnaires significantly decreased from pre-treatment to post-treatment in BAI (26.65 to 14.50; p<0.05) and STAI  (54.15 to 45.50; p<0.05).  HAM-A mean scores decreased from 25.00 to 15.00 (p<0.11).


Repetto et al.  Pers and Ubiq Computing.  2011.

For more information, please contact us

Contact Us

reVIVE™ is not yet available in the United States